Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT06687967

PHASE3

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)

Sponsor: Sanofi

View on ClinicalTrials.gov

Summary

This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.

Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

142

Start Date

2024-11-28

Completion Date

2026-08-31

Last Updated

2026-01-21

Healthy Volunteers

Conditions

Lichen Simplex Chronicus

Interventions

DRUG

Dupilumab

Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection

DRUG

Placebo

Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection

Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply (at screening and baseline unless otherwise specified): * Participant must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent. * Participants with moderate-to-severe LSC, as defined by Investigator's Global Assessment (IGA) score ≥3 and one or more of the following: * at least 1 single anogenital lesion; * at least 2 lesions including 1 lesion of ≥3 cm in diameter; * at least 1 severe lesion (IGA score = 4). * History of LSC for at least 6 months prior to the screening visit. * On the Worst-Itch Numerical Rating Scale (WI-NRS) ranging from 0 to 10, participants must have an average worst-itch of LSC score of ≥7 in the 7 days prior to Day 1. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. For participants who do not have at least 4 daily scores reported during the 7 days immediately preceding the planned randomization date, randomization can be postponed until this requirement is met, but without exceeding the 28-day maximum duration of the screening period. * History of failing a 2-week course of medium-to-superpotent topical corticosteroid (TCS) +/- topical calcineurin inhibitor (TCI) for the treatment of LSC within the last 6 months, unless TCS/TCI are medically not advisable. Patients with documented systemic treatment for LSC (other than antihistamines) in the past 6 months are also considered as inadequate responders to topical treatments and are potentially eligible for treatment with dupilumab after appropriate washout. * Appropriate contraceptive measures Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply (at screening and baseline unless otherwise specified): * Participants diagnosed with active lesions of prurigo nodularis (broadly distributed nodules) or active lesions of atopic dermatitis (AD) within 6 months, contact dermatitis, psoriasis, cutaneous T-cell lymphoma (CTCL) XE "CTCL" \\f Abbreviation \\t "cutaneous T-cell lymphoma" (or suspected of CTCL), vulvar lichen planus, or vulvar lichen sclerosus. * Presence of skin morbidities other than LSC that, in the opinion of the Investigator, may interfere with the assessment of the study outcomes. For example: scabies, insect bite, folliculitis, lymphomatoid papulosis, chronic actinic dermatitis, dermatitis herpetiformis, sporotrichosis, bullous disease, lichen planus hypertrophicus. * Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study. * Severe psychiatric disease that, in the Investigator's judgement, would affect the study intervention evaluation. * Having received or planning to use any of the treatments within the timeframe as specified in the protocol. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (63)

Dermatology Research Associates - Los Angeles- Site Number : 8400004

Los Angeles, California, United States

Quality Care Clinical Research- Site Number : 8400034

Miami, Florida, United States

Michigan Center for Research Company- Site Number : 8400013

Clarkston, Michigan, United States

JDR Dermatology Research- Site Number : 8400023

Las Vegas, Nevada, United States

Equity Medical- Site Number : 8400017

New York, New York, United States

Onsite Clinical Solutions - Huntersville- Site Number : 8400033

Huntersville, North Carolina, United States

Wake Forest University Health Sciences- Site Number : 8400028

Winston-Salem, North Carolina, United States

Red River Research Partners - Fargo- Site Number : 8400007

Fargo, North Dakota, United States

Center for Clinical Studies - Houston - Binz Street- Site Number : 8400011

Houston, Texas, United States

MedCare Pharma - Houston - Cypress Creek Parkway- Site Number : 8400014

Houston, Texas, United States

Care Access - Arlington- Site Number : 8400022

Arlington, Virginia, United States

Investigational Site Number : 0320003

Rosario, Santa Fe Province, Argentina

Investigational Site Number : 0320001

Buenos Aires, Argentina

Investigational Site Number : 0320004

Buenos Aires, Argentina

Investigational Site Number : 0320002

Mendoza, Argentina

Investigational Site Number : 1240005

Edmonton, Alberta, Canada

Investigational Site Number : 1240001

London, Ontario, Canada

Investigational Site Number : 1240007

Mississauga, Ontario, Canada

Investigational Site Number : 1240009

Montreal, Quebec, Canada

Investigational Site Number : 1240008

Québec, Quebec, Canada

Investigational Site Number : 1240010

Regina, Saskatchewan, Canada

Investigational Site Number : 1240002

Saskatoon, Saskatchewan, Canada

Investigational Site Number : 1520002

Santiago, Reg Metropolitana de Santiago, Chile

Investigational Site Number : 1520001

Santiago, Reg Metropolitana de Santiago, Chile

Investigational Site Number : 1520003

Santiago, Reg Metropolitana de Santiago, Chile

Investigational Site Number : 1560002

Beijing, China

Investigational Site Number : 1560004

Hangzhou, China

Investigational Site Number : 1560001

Shanghai, China

Investigational Site Number : 1560003

Shijiazhuang, China

Investigational Site Number : 1560005

Suzhou, China

Investigational Site Number : 2030001

Ostrava, Czechia

Investigational Site Number : 2760003

Bad Bentheim, Germany

Investigational Site Number : 2760001

Magdeburg, Germany

Investigational Site Number : 3000001

Athens, Greece

Investigational Site Number : 3000002

Thessaloniki, Greece

Investigational Site Number : 3000003

Thessaloniki, Greece

Investigational Site Number : 3480001

Debrecen, Hungary

Investigational Site Number : 3480002

Kaposvár, Hungary

Investigational Site Number : 3800001

Rome, Roma, Italy

Investigational Site Number : 3800002

Bologna, Italy

Investigational Site Number : 3920002

Ebina-shi, Kanagawa, Japan

Investigational Site Number : 3920001

Kamiamakusa, Kumamoto, Japan

Investigational Site Number : 3920007

Sakai, Osaka, Japan

Investigational Site Number : 3920003

Tachikawa, Tokyo, Japan

Investigational Site Number : 3920009

Fukuoka, Japan

Investigational Site Number : 3920005

Kagoshima, Japan

Investigational Site Number : 4840003

Aguascalientes, Mexico

Investigational Site Number : 4840001

Chihuahua City, Mexico

Investigational Site Number : 6200002

Coimbra, Portugal

Investigational Site Number : 6200003

Lisbon, Portugal

Investigational Site Number : 6200001

Porto, Portugal

Investigational Site Number : 7240003

Barcelona, Barcelona [Barcelona], Spain

Investigational Site Number : 7240005

Barcelona, Catalunya [Cataluña], Spain

Investigational Site Number : 7240002

Barcelona, Catalunya [Cataluña], Spain

Investigational Site Number : 7240004

Valencia, Spain

Investigational Site Number : 1580002

Kaohsiung City, Taiwan

Investigational Site Number : 1580003

New Taipei City, Taiwan

Investigational Site Number : 1580001

Taipei, Taiwan

Investigational Site Number : 7920003

Adapazarı, Turkey (Türkiye)

Investigational Site Number : 7920002

Istanbul, Turkey (Türkiye)

Investigational Site Number : 7920001

Samsun, Turkey (Türkiye)

Investigational Site Number : 8260002

Milton Keynes, Buckinghamshire, United Kingdom

Investigational Site Number : 8260001

London, England, United Kingdom

Clinical Research Directory

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (63)